Head of Regulatory Affairs
ARTBIO
Head of Regulatory Affairs
ARTBIO
Develops radioligand therapies for cancer
The Head of Regulatory Affairs leads ARTBIO’s regulatory function for clinical-stage radiopharmaceutical programs, ensuring clear strategy, compliant execution, and effective engagement with health authorities. This is a key leadership position that requires a deep understanding of regulatory processes and a proven track record of successfully navigating regulatory landscapes in the biotech or pharmaceutical industry.
ARTBIO develops targeted radioligand therapies to treat cancer. Its lead program AB001 has entered first-in-human studies, and two other targets, ABA and ABB, are under development. These therapies use radioligands that bind to tumor cells with high affinity and deliver radiation directly to tumors while minimizing damage to healthy tissue. ARTBIO differentiates itself through a differentiated pipeline, strong collaborations with F Prime and Radforsk, and a team with decades of experience in drug development, aiming to advance cancer therapies from clinical trials to market. The company’s goal is to bring its therapies to healthcare providers and patients, generating revenue through sales and potential licensing as its treatments gain regulatory approval.
Explore more opportunities at ARTBIO